VEGFA and non-small cell lung carcinoma: Nintedanib is an indolinone derivative that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor (VEGF) receptors 1–3, platelet‐derived growth factor (PDGF) receptors and fibroblast growth factor (FGF) receptors.9 In a preclinical study, nintedanib demonstrated potent antitumor effects in xenograft models of human lung cancer.10 Previous clinical trials on nintedanib for NSCLC are summarized in Table 2.